FDA Grants Orphan Drug Designation to Biodel’s Glucagon for Prevention of Hypoglycemia in Congenital Hyperinsulinism Population

FDA Grants Orphan Drug Designation to Biodel’s Glucagon for Prevention of Hypoglycemia in Congenital Hyperinsulinism Population

[at noodls] – FDA Grants Orphan Drug Designation to Biodel’s Glucagon for Prevention of Hypoglycemia in Congenital Hyperinsulinism Population DANBURY, Conn., Dec. 6, 2012 (GLOBE NEWSWIRE) — Biodel Inc. (Nasdaq:BIOD) … more

View todays social media effects on BIOD

View the latest stocks trending across Twitter. Click to view dashboard

See who Biodel is hiring next, click here to view

Share this post

Comments (0)